Harbin Gloria Pharmaceuticals took a $600 million stake in a subsidiary of SINOPHARM GROUP whose lead product is an oral insulin candidate being codeveloped with Israeli biotech Oramed Pharmaceuticals.
GSK and 23andMe unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery.
PureTech Health, a clinical-stage biopharmaceutical company developing novel medicines focused on the Brain-Immune-Gut (BIG) Axis, announced that it has entered into a multiyear collaboration with Roche.
SK Holdings, the parent company of South Korea’s third-largest conglomerate SK Group, announced that it has acquired a 100 percent stake in AMPAC Fine Chemicals, a US-based contract manufacturer of APIs.
Scientists at the Harvard John A. Paulson School of Engineering and Applied Sciences have developed an oral delivery method that could dramatically transform the way in which diabetics keep their blood sugar levels in check.
Celltrion signed an agreement with Yonsei University Health System on the joint development of Fc-Saxatilin, a candidate drug for ischemic strokes in a bid to develop new biopharmaceuticals for cerebrovascular diseases.
Eligo Bioscience, the French microbiome company, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge.
CERENIS Therapeutics, an international biopharmaceutical company dedicated to the development of HDL-based innovative therapies, signed a strategic partnership with the University of North Texas Health Science Center.